Sponsored Links 
Top 5 Healthcare Funds
Print
ShareThe healthcare sector has clearly felt the impact of the new legislation enacted by Congress. The industry faces the prospect of gaining numerous new customers as well as facing the prospect of substantially higher fees. But the sector as a whole continues to perform well despite these developments and the recent economic slowdown. However, investing in healthcare securities requires clear insight into the nuances of drug discovery and new advances in biotechnology. Mutual funds offer a superior option to investing in this sector since they possess the advantages of professional management and disciplined research.
Below we will share with you 5 top rated health funds. Each has earned a Zacks #1 Rank (Strong Buy) as we expect the fund to outperform its peers in the future. To view the Zacks Rank and past performance of all health funds, then click here.
Delaware Healthcare A (DLHAX) seeks long-term capital growth. It invests the majority of its assets in equity securities of healthcare companies. It invests in domestic and foreign companies with a wide range of market capitalizations. It may also purchase securities issued by emerging market companies. The health fund returned 83.84% over the last one year period.
The Fund Manager is Liu-Er Chen and he has managed this health fund since 2007.
Kinetics Medical No Load (MEDRX) invests at least 80% of its assets in domestic and foreign healthcare companies engaged in medical research. It focuses on companies whose primary operations include drug discovery and cancer research. It primarily purchases stocks convertible securities, warrants and ADRs. Up to 20% of its assets may be invested in unrated debt securities as well as those rated below investment grade. It is a no load fund.
The health fund returned 42.32% in the last one year and has a five year annualized return of 6.76%.
Manning & Napier Life Sciences (EXLSX) seeks capital appreciation by investing heavily in securities of companies from the life sciences sector. Domestic and foreign equity, ADRs and U.S. dollar denominated foreign securities make up the majority of its assets. The health fund has a five year annualized return of 6.69%.
The health fund has a minimum initial investment of $2,000 and an expense ratio of 1.12% compared to a category average of 1.98%.
Rydex Biotechnology (RYOIX) invests the majority of its assets in equity securities and derivatives issued by domestic biotechnology companies. It is non-diversified and seeks long-term capital growth. The health fund returned 41.55% in the last one year period and has a three year annualized return of 6.55%.
Michael J. Dellapa is the fund manager and he has managed this health fund since 2006.
Franklin Biotechnology Discovery A (FBDIX) seeks long-term capital growth. It invests the majority of its assets in biotechnology and discovery research companies located in the U.S. or Europe as well as other countries. It may also utilize a smaller portion of its assets to acquire debt securities issued from these countries. The health fund returned 24.36% over the last one year period.
This healthcare fund has an expense ratio of 1.32% compared to a category average of 1.98%.
To view the Zacks Rank and past performance of all Healthcare Funds, then click here.
About Zacks Mutual Fund Rank
By applying the Zacks Rank to mutual funds, investors can find funds that not only outpaced the market in the past but are also expected to outperform going forward. Learn more about the Zacks Mutual Fund Rank at http://www.zacks.com/funds/mutualfund/.
Read the full analyst report on DLHAX
Read the full analyst report on MEDRX
Read the full analyst report on EXLSX
Read the full analyst report on RYOIX
Read the full analyst report on FBDIX
Loading Stories...
|
||||||||||||||||||
More Zacks Resources
More Zacks Links
| Market Summary | May 26, 2012 07:48 am ET |
-74.92